Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety and Efficacy of CD19/BCMA CAR T-cell Therapy for Refractory Systemic Lupus Erythematosus

NCT07266337 is registered in ClinicalTrials.gov with Chengdu Ucello Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07266337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07266337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety and Efficacy of CD19/BCMA CAR T-cell Therapy for Refractory Systemic Lupus Erythematosus
Lead sponsor
Chengdu Ucello Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 10, 2025
Completion date
December 31, 2037
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sle - systemic lupus erythematosus